ArticleFrontiers in pharmacology2026
Comparative pharmacovigilance of non-benzodiazepine receptor agonists versus dual orexin receptor antagonists for insomnia in older adults.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The accelerating global aging trend has positioned insomnia in the elderly as a major public health challenge. Although cognitive behavioral therapy is the first-line intervention, pharmacological treatment remains widely used. However, significant safety concerns exist regarding the use of traditional non-benzodiazepine sedative-hypnotics (nBZRAs) in older adults, while long-term real-world safety evidence for newer dual orexin receptor antagonists (DORAs) remains scarce. Addressing this evidence gap is critical for guiding safe medication use in the aging population. Methods: We conducted a pharmacovigilance study utilizing the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, covering reports from the first quarter of 2004 to the second quarter of 2025. We included reports for patients aged ≥65 years where a target nBZRA or DORA was listed as the primary suspect drug. A comprehensive disproportionality analysis was performed using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM), with stringent thresholds to minimize false positives. Results: A total of 5,447 reports for elderly patients were analyzed. The study revealed distinct adverse event profiles between the two drug classes. nBZRAs, particularly eszopiclone, showed the strongest signals related to therapeutic failure (e.g., "Drug ineffective," "Insomnia") alongside a unique signal for "Dysgeusia". In contrast, DORAs exhibited strong and consistent signals for "Dream-abnormality" events concordant with their sleep-wake modulation mechanism, including "Nightmare," "Abnormal dreams," and "Hallucination". Notably, none of the studied drugs generated a statistically significant signal for "Fall" within this dataset. System Organ Class analysis showed that psychiatric and nervous system disorders had the highest incidence. Conclusion: These findings highlight distinct safety profiles: nBZRAs are linked to therapeutic failure and dysgeusia, while DORAs are associated with neuropsychiatric events such as nightmares and hallucinations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.